Eaton Vance Management Has $40.93 Million Holdings in Emergent BioSolutions Inc. (NYSE:EBS)


Share on StockTwits

Eaton Vance Management grew its holdings in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 20.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 456,768 shares of the biopharmaceutical company’s stock after purchasing an additional 77,233 shares during the period. Eaton Vance Management owned about 0.86% of Emergent BioSolutions worth $40,927,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in EBS. ProShare Advisors LLC grew its position in shares of Emergent BioSolutions by 36.2% during the 3rd quarter. ProShare Advisors LLC now owns 9,284 shares of the biopharmaceutical company’s stock worth $959,000 after purchasing an additional 2,470 shares in the last quarter. Allianz Asset Management GmbH grew its position in shares of Emergent BioSolutions by 2.5% during the 3rd quarter. Allianz Asset Management GmbH now owns 37,218 shares of the biopharmaceutical company’s stock worth $3,846,000 after purchasing an additional 902 shares in the last quarter. Truist Financial Corp grew its position in shares of Emergent BioSolutions by 1.3% during the 3rd quarter. Truist Financial Corp now owns 31,497 shares of the biopharmaceutical company’s stock worth $3,254,000 after purchasing an additional 394 shares in the last quarter. Advisors Asset Management Inc. grew its position in shares of Emergent BioSolutions by 98.5% during the 3rd quarter. Advisors Asset Management Inc. now owns 2,721 shares of the biopharmaceutical company’s stock worth $281,000 after purchasing an additional 1,350 shares in the last quarter. Finally, Engineers Gate Manager LP acquired a new position in shares of Emergent BioSolutions during the 3rd quarter worth approximately $1,711,000. Hedge funds and other institutional investors own 80.23% of the company’s stock.

EBS has been the topic of a number of analyst reports. Chardan Capital upgraded shares of Emergent BioSolutions from a “neutral” rating to a “buy” rating and set a $112.00 target price on the stock in a research report on Tuesday, March 2nd. Benchmark assumed coverage on shares of Emergent BioSolutions in a report on Wednesday. They set a “buy” rating and a $150.00 price target for the company. Finally, Wells Fargo & Company downgraded shares of Emergent BioSolutions from an “overweight” rating to an “equal weight” rating and set a $110.00 price target for the company. in a report on Friday, January 8th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $107.29.

In related news, CEO Robert Kramer sold 21,900 shares of the stock in a transaction that occurred on Thursday, January 21st. The shares were sold at an average price of $110.03, for a total value of $2,409,657.00. Following the completion of the transaction, the chief executive officer now owns 141,442 shares of the company’s stock, valued at approximately $15,562,863.26. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Sue Bailey sold 8,168 shares of the stock in a transaction that occurred on Thursday, March 4th. The shares were sold at an average price of $92.37, for a total transaction of $754,478.16. Following the completion of the transaction, the director now directly owns 24,427 shares of the company’s stock, valued at approximately $2,256,321.99. The disclosure for this sale can be found here. In the last three months, insiders sold 49,094 shares of company stock valued at $5,181,081. 14.10% of the stock is owned by insiders.

Shares of Emergent BioSolutions stock opened at $78.86 on Thursday. The company has a market cap of $4.20 billion, a PE ratio of 25.36 and a beta of 1.26. The company has a current ratio of 3.20, a quick ratio of 2.30 and a debt-to-equity ratio of 0.68. The company has a 50 day moving average of $93.73 and a 200-day moving average of $96.70. Emergent BioSolutions Inc. has a 1-year low of $59.32 and a 1-year high of $137.61.

Emergent BioSolutions (NYSE:EBS) last issued its quarterly earnings data on Wednesday, February 17th. The biopharmaceutical company reported $3.67 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.72 by $0.95. The business had revenue of $583.00 million during the quarter, compared to the consensus estimate of $588.39 million. Emergent BioSolutions had a net margin of 12.50% and a return on equity of 26.68%. Research analysts forecast that Emergent BioSolutions Inc. will post 6.94 earnings per share for the current year.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care.

Further Reading: What is basic economics?

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent BioSolutions Inc. (NYSE:EBS).

Institutional Ownership by Quarter for Emergent BioSolutions (NYSE:EBS)

Receive News & Ratings for Emergent BioSolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent BioSolutions and related companies with MarketBeat.com's FREE daily email newsletter.